Related Experiment Video
Updated: May 27, 2026
07:23
Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome
Published on: June 15, 2016
STAT3 activation in monocytes accelerates liver cancer progression
Wen-Yong Wu1, Jun Li, Zheng-Sheng Wu
1Department of General Surgery, First Affiliated Hospital of Anhui MedicalUniversity, Anhui, Hefei, People’s Republic of China.
BMC Cancer
|December 6, 2011
Summary
Activated STAT3 in monocytes promotes liver cancer growth. Blocking STAT3 in monocytes may be a new liver cancer therapy strategy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Signal transducer and activator of transcription 3 (STAT3) is crucial for cell functions but its role in monocytes during hepatocellular carcinoma (HCC) development is unclear.
- Aberrant STAT3 signaling is implicated in various cancers, including HCC initiation and progression.
- Understanding STAT3's role in monocytes is key to developing novel HCC therapies.
Purpose of the Study:
- To investigate the role of STAT3 activation in monocytes in the development of HCC.
- To explore STAT3 as a potential therapeutic target in liver cancer.
Main Methods:
- Immunohistochemical analysis of phosphorylated STAT3 in HCC patient tissues.
- In vitro co-culture systems to assess HCC cell growth.
- In vivo studies using diethylnitrosamine (DEN)-induced HCC in mice.
- Real-time PCR to analyze gene expression related to proliferation and cell arrest.
Main Results:
- Phosphorylated STAT3 was detected in HCC tissues, specifically in tumor cells and monocytes.
- Monocyte STAT3 expression correlated with advanced HCC stage and poor prognosis.
- Monocytes promoted HCC growth via the IL-6/STAT3 pathway; a STAT3 inhibitor (NSC 74859) suppressed tumor growth, induced apoptosis, and reduced inflammation in a mouse model.
Conclusions:
- Constitutively activated STAT3 monocytes contribute to liver tumorigenesis.
- Targeting STAT3 in tumor-infiltrating inflammatory cells presents a promising therapeutic strategy for liver cancer.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...